Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as NAD+ increasing precursors
Compositions are provided including nicotinic acid riboside (“NAR”), and derivatives thereof including 1-(2′,3′,5′-triacetyl-beta-D-ribofuranosyl)-nicotinic acid (“NAR triacetate” or “NARTA”); or derivatives of a reduced form of nicotinic acid riboside (“NARH”), including 1-(2′,3′,5′-triacetyl-beta-D-ribofuranosyl)-1,4-dihydronicotinic acid (“NARH triacetate” or “NARH-TA”); or derivatives of nicotinamide riboside (“NR”), including 1-(2′,3′,5′-triacetyl-beta-D-ribofuranosyl)-nicotinamide (“NR triacetate” or “NRTA”); derivatives of a reduced form of nicotinamide riboside (“NRH”), including 1-(2′,3′,5′-triacetyl-beta-D-ribofuranosyl)-1,4-dihydronicotinamide (“NRH triacetate” or “NRH-TA”); or salts or prodrugs thereof, for use in food or beverage applications, pharmaceutical formulations, or as a dietary supplement. Methods of using the compounds above to promote the increase of intracellular levels of nicotinamide adenine dinucleotide (“NAD+”) or NADH in cells and tissues for improving cell and tissue survival or overall cell and tissue health are provided.
1. A method for increasing intracellular NAD+ in a subject mammal, comprising
delivering to the mammal in need of such treatment an effective amount of at least one compound of formula (I-Ha), or a salt, solvate, or prodrug thereof:
wherein R 6 is selected from the group consisting of hydrogen, —C(O)R′, —C(O)OR′, —C(O)NHR′, substituted or unsubstituted (C 1 -C 8 )alkyl, substituted or unsubstituted (C 3 -C 8 )cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heterocycle;
R′ is selected from the group consisting of hydrogen, —(C 1 -C 8 )alkyl, —(C 3 -C 8 )cycloalkyl, aryl, heteroaryl, heterocycle, aryl(C 1 -C 4 )alkyl, and heterocycle(C 1 -C 4 )alkyl; and
R 7 and R 8 are independently selected from the group consisting of hydrogen, —C(O)R′, —C(O)OR′, —C(O)NHR′, substituted or unsubstituted (C 1 -C 8 )alkyl, substituted or unsubstituted (C 3 -C 8 )cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycle, substituted or unsubstituted aryl(C 1 -C 4 )alkyl, and substituted or unsubstituted heterocycle(C 1 -C 4 )alkyl;
provided that when R 6 is —C(O)R′, and R′ is —(C 1 -C 8 )alkyl, then each of R 7 and R 8 is not hydrogen or —C(O)R′ or —C(O)OR′;
further provided that when R 6 is —C(O)OR′, and R′ is —(C 1 -C 8 )alkyl, then each of R 7 and R 8 is not hydrogen or —C(O)R′ or —C(O)OR′; or
a compound of formula (II-Hc), or a salt, solvate, or prodrug thereof:
wherein R 6 is selected from the group consisting of hydrogen, —C(O)R′, —C(O)OR′, —C(O)NHR′, substituted or unsubstituted (C 1 -C 8 )alkyl, substituted or unsubstituted (C 3 -C 8 )cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heterocycle;
R′ is selected from the group consisting of hydrogen, —(C 1 -C 8 )alkyl, —(C 3 -C 4 )cycloalkyl, aryl, heteroaryl, heterocycle, aryl(C 1 - C 4 )alkyl, and heterocycle(C 1 - C 4 )alkyl; and
R 7 and R 8 are independently selected from the group consisting of hydrogen, —C(O)R′, —C(O)OR′, —C(O)NHR′, substituted or unsubstituted (C 1 -C 8 )alkyl, substituted or unsubstituted (C 3 -C 8 )cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycle, substituted or unsubstituted aryl(c 1 -C 4 )alkyl, and substituted or unsubstituted heterocycle(C 1 -C 4 )alkyl and wherein R 1 is selected from hydrogen and (C 1 -C 4 )alkyl;
wherein NAD+ biosynthesis is increased.
2. The method according to claim 1 , wherein the compound of formula (II-Hc) is NARH or NARH-TA.
3. A method for increasing intracellular NAD+ in a subject mammal, comprising
delivering to the mammal in need of such treatment an effective amount of at least one compound of formula (Ia), or a salt, solvate, or prodrug thereof:
wherein R 6 is selected from the group consisting of hydrogen, —C(O)R′, —C(O)OR′, —C(O)NHR′, substituted or unsubstituted (C 1 -C 8 )alkyl, substituted or unsubstituted (C 3 -C 8 )cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heterocycle;
R′ is selected from the group consisting of hydrogen, —(C 1 -C 8 )alkyl, —(C 3 -C 8 )cycloalkyl, aryl, heteroaryl, heterocycle, aryl(C 1 -C 4 )alkyl, and heterocycle(C 1 -C 4 )alkyl; and
R 7 and R 8 are independently selected from the group consisting of hydrogen, —C(O)R′, —C(O)OR′, —C(O)NHR′, substituted or unsubstituted (C 1 -C 8 )alkyl, substituted or unsubstituted (C 3 -C 8 )cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycle, substituted or unsubstituted aryl(C 1 -C 4 )alkyl, and substituted or unsubstituted heterocycle(C 1 -C 4 )alkyl;
provided that R 6 , R 7 , and R 8 are not all simultaneously hydrogen;
further provided that when R 6 is —C(O)R′, and R′ is —(C 1 -C 8 )alkyl, then each of R 7 and R 8 is not hydrogen or —C(O)R′ or —C(O)OR′;
further provided that when R 6 is —C(O)OR′, and R′ is —(C 1 -C 8 )alkyl, then each of R 7 and R 8 is not hydrogen or —C(O)R′ or —C(O)R′; or
a compound of formula (IIa), or a salt, solvate, or prodrug thereof:
wherein R 6 is selected from the group consisting of hydrogen, —C(O)R′, —C(O)OR′, —C(O)NHR′, substituted or unsubstituted (C 1 -C 8 )alkyl, substituted or unsubstituted (C 3 -C 8 )cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heterocycle;
R′ is selected from the group consisting of hydrogen, —(C 1 -C 8 )alkyl, —(C 3 -C 4 )cycloalkyl, aryl, heteroaryl, heterocycle, aryl(C 1 - C 4 )alkyl, and heterocycle(C 1 - C 4 )alkyl; and
R 7 and R 8 are independently selected from the group consisting of hydrogen, —C(O)R′, —C(O)OR′, —C(O)NHR′, substituted or unsubstituted (C 1 -C 8 )alkyl, substituted or unsubstituted (C 3 -C 8 )cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycle, substituted or unsubstituted aryl(c 1 -C 4 )alkyl, and substituted or unsubstituted heterocycle(C 1 -C 4 )alkyl and wherein R 1 is selected from hydrogen and (C 1 -C 4 )alkyl;
provided that R 1 , R 6 , R 7 , and R 8 are not all simultaneously hydrogen;
wherein NAD+ biosynthesis is increased.
4. The method according to claim 3 , wherein the compound of formula (IIa) is NARTA.
5. A method for increasing intracellular NADH in a subject mammal, comprising
delivering to the mammal in need of such treatment an effective amount of at least one compound of formula (I-Ha), or a salt, solvate, or prodrug thereof:
wherein R 6 is selected from the group consisting of hydrogen, —C(O)R′, —C(O)OR′, —C(O)NHR′, substituted or unsubstituted (C 1 -C 8 )alkyl, substituted or unsubstituted (C 3 -C 8 )cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heterocycle;
R′ is selected from the group consisting of hydrogen, —(C 1 -C 8 )alkyl, —(C 3 -C 8 )cycloalkyl, aryl, heteroaryl, heterocycle, aryl(C 1 -C 4 )alkyl, and heterocycle(C 1 -C 4 )alkyl; and
R 7 and R 8 are independently selected from the group consisting of hydrogen, —C(O)R′, —C(O)OR′, —C(O)NHR′, substituted or unsubstituted (C 1 -C 8 )alkyl, substituted or unsubstituted (C 3 -C 8 )cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycle, substituted or unsubstituted aryl(C 1 -C 4 )alkyl, and substituted or unsubstituted heterocycle(C 1 -C 4 )alkyl; or
a compound of formula (II-Hc), or a salt, solvate, or prodrug thereof:
wherein R 6 is selected from the group consisting of hydrogen, —C(O)R′, —C(O)OR′, —C(O)NHR′, substituted or unsubstituted (C 1 -C 8 )alkyl, substituted or unsubstituted (C 3 -C 8 )cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heterocycle;
R′ is selected from the group consisting of hydrogen, —(C 1 -C 8 )alkyl, —(C 3 -C 4 )cycloalkyl, aryl, heteroaryl, heterocycle, aryl(C 1 - C 4 )alkyl, and heterocycle(C 1 - C 4 )alkyl; and
R 7 and R 8 are independently selected from the group consisting of hydrogen, —C(O)R′, —C(O)OR′, —C(O)NHR′, substituted or unsubstituted (C 1 -C 8 )alkyl, substituted or unsubstituted (C 3 -C 8 )cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycle, substituted or unsubstituted aryl(c 1 -C 4 )alkyl, and substituted or unsubstituted heterocycle(C 1 -C 4 )alkyl and wherein R 1 is selected from hydrogen and (C 1 -C 4 )alkyl;
wherein NADH biosynthesis is increased.
6. The method according to claim 5 , wherein the compound of formula (I-Ha) is NRH or NRH-TA.
7. The method according to claim 5 , wherein the compound of formula (II-Hc) is NARH or NARH-TA.
8. A method for increasing intracellular NAD+ in a subject mammal, comprising delivering to the mammal in need of such treatment an effective amount of NRTA, or a salt, solvate, or prodrug thereof, wherein NAD+ biosynthesis is increased.